PERIDEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PERIDEX (PERIDEX).
Chlorhexidine, a bisbiguanide antiseptic, disrupts microbial cell membranes, leading to leakage of cytoplasmic contents and cell death. It exhibits broad-spectrum bactericidal and fungicidal activity.
| Metabolism | Chlorhexidine is poorly absorbed from the gastrointestinal tract; absorbed drug is excreted unchanged in urine. No significant hepatic metabolism. |
| Excretion | Primarily renal, with approximately 30% of absorbed dose excreted unchanged in urine. Biliary/fecal excretion accounts for 70%, with glucuronide conjugates and minor metabolites. |
| Half-life | Terminal elimination half-life is 17-20 hours. Steady-state achieved in 3-5 days. In renal impairment, half-life may extend to 40 hours. |
| Protein binding | Less than 20% bound to plasma proteins. Not extensively bound to albumin; binding is nonspecific and reversible. |
| Volume of Distribution | Approximately 0.4 L/kg. Distributes into oral mucosa, saliva (concentrations 10-100 times plasma), and other tissues. Low systemic distribution due to poor oral absorption. |
| Bioavailability | Oral (as rinse): Approximately 2% systemically absorbed due to low buccal permeability and extensive first-pass metabolism. Ingested dose is mostly unabsorbed. |
| Onset of Action | Oral: Mucosal adherence within seconds; antibacterial activity detectable within 2 hours after first dose. Dental use: Clinical effect on plaque formation within 2-3 days. |
| Duration of Action | Antibacterial substantivity persists for 12 hours after single dose. With twice-daily rinsing, plaque reduction maintained throughout treatment. Tooth discoloration may be delayed for weeks. |
15 mL swish for 30 seconds twice daily, then expectorate; do not swallow.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for use in children under 18 years due to lack of safety and efficacy data. |
| Geriatric use | Use same as adult dosing; monitor for oral mucosal irritation and potential swallowing difficulties. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PERIDEX (PERIDEX).
| Breastfeeding | It is not known whether chlorhexidine is excreted in human milk. Because many drugs are excreted in human milk and due to the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio: not available. |
| Teratogenic Risk | Pregnancy Category C. No adequate well-controlled studies in pregnant women. Systemic absorption following topical oral use is minimal; however, chlorhexidine has been associated with fetal toxicity in animal studies at high doses. First trimester: risk cannot be ruled out; use only if clearly needed. Second and third trimesters: no known specific risks, but data insufficient to guarantee safety. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Known hypersensitivity to chlorhexidine or any component of the formulation","Use in eyes or inner ear"]
| Precautions | ["Anaphylaxis and hypersensitivity reactions","Staining of teeth, dental restorations, and tongue","Alteration in taste perception (dysgeusia)","Parotid gland swelling","Superficial desquamation of oral mucosa","Ototoxicity if instilled into the ear"] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring required for topical oral use due to negligible systemic absorption. In case of accidental ingestion, observe for symptoms of mucosal irritation, CNS depression, or respiratory distress. |
| Fertility Effects | No known effects on fertility from topical oral use. Animal studies with systemic administration at high doses have shown impaired fertility, but relevance to human topical use is unlikely. |